On Demand Webinar

Biomarker strategy: NGS & AI with applications in drug and diagnostic test discovery and development

Early cancer diagnostic test, companion diagnostic and biomarker discovery are key components of modern personalized medicine strategies providing many benefits for early cancer detection, recruitment, and stratifications of patients into subgroups, treatment selection, minimal residual disease surveillance and monitoring.

Watch Now

In this webinar, we will:

• Integrating Biomarker Strategies in Preclinical Research: Explore how incorporating biomarker strategies and NGS and AI approaches, at the early stages of preclinical research can enhance the drug discovery and development process. Understand how this strategic integration aims to mitigate risks and improve the success rates of clinical trials.
  
  
• Challenges and Opportunities in Biomarker Strategy: Delve into the complexities and benefits of combining NGS and AI in biomarker strategy development. Discuss how these technologies are shaping the future of liquid biopsies and their translation from preclinical studies to clinical trials.
  
  
• Case Study on Novel Fusion Point Discovery: Gain insights from a case study on the identification of a novel fusion points panel using NGS and AI. Learn about the potential applications of these findings in liquid biopsies for early detection and prognosis in pancreatic cancer patients.

Watch Now

About The Presenter:

Patrick Page, PhD, MBA, Director, Corporate Development, Crown Bioscience

Patrick oversees European partnerships, identifying and leading negotiation and licensing novel technologies or models, and being involved in corporate strategy and business planning. He has comprehensive knowledge of pharma, biotech, CRO/CDMO industry. Prior to joining Crown Bioscience, Patrick worked as project director at AstraZeneca and MerckSerono. He established, led or executed innovative small molecule or biological molecule projects and strategies in different therapeutic indications from target identification to PhII clinical trials. He designed 3 drugs Ebopiprant, Setanaxib and Nolasiban and has taken 12 more compounds across clinical development in oncology, respiratory, metabolic and cardiovascular diseases, fibrosis, and reproductive health. Patrick also co-founded and was CEO/CSO/COO of several biotech companies, Genkyotex in 2006 now acquired by Calliditas, Epire-med and Conicmeds, as well as two consultancy firms Huperion and Decode Pharma Partners. Patrick became Corporate Development Director at Crown Bioscience Inc. in 2021, working closely with multiple stakeholders internally and externally to support the Corporate Strategy and Development of the company. Patrick has authored 50+ publications and patents.